Bookmark and Share

Last Minute:          For more news, click here.

Authentication
       
       
Remember me? 

Fall of
--0.82 (+0.99%) Celgene Corporati - [Ticker: CELG]Chart Celgene Corporati  News Celgene Corporati  Download Historical Prices for Metastock Celgene Corporati and Others  Technical Analysis Celgene Corporati  
Last Trade70.16Last Trade Time2018-11-29 - 00:00:00
Variation--0.82 (+0.99%)Open70.40
High71.03Low68.93
Volume6,015,655Average Volume (3m)0
YieldBid / Ask100.75 x 400 - 100.78 x 100
Former Close70.9852 Week Range[0.00 - 0.00]
PER0.00%EPS0.00
Ex-Dividend DateDividend Payment
Market Capitalization0 1 Year Price-Target0.00
Note: The data may have some minutes of delay.
Watch more quotes

Intraday   5 days   1 month   3 months   6 months   1 year   2 years   5 years   10 years            Use this chart on your website!
Celgene Corporati -  [Ticker: CELG] chart
Change to Celgene Corporati Interactive Technical Analysis Chart

Last 10 Forum Topics about Celgene Corporati:
No topics about Celgene Corporati [CELG] have been found, but a search on the Forum for more topics related to Celgene Corporati is advised.

 News about Celgene Corporati [CELG]:   (ordered by relevance)
Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency  Investing News Network Aptose to Hold Corporate Update Monday, December 13th  Investing News Network Title: Bristol-Myers Squibb Company and Celgene Corporation, In the Matter of (Administrative)  marketscreener.com BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY  Yahoo Finance INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set  Yahoo Finance Federal Circuit Affirms Dismissal of Celgene's Hatch-Waxman Suit Against Mylan  IPWatchdog.com Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS  Investing News Network Lymphoma Market to Rear Excessive Growth During 2021 | Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co. Inc., Hoffmann-La Roche Ltd.  Taiwan News Celgene sues to protect patents for blockbuster cancer drug Revlimid  Lawyerly 8,000 plus Attend Boosh Sponsored Planted Expo in Vancouver  Investing News Network Orphan Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030  Yahoo Finance Amgen To Present At The 2021 Piper Sandler Healthcare Conference  Investing News Network BMY, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead  GlobeNewswire SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF  GlobeNewswire Case Summary: Juno Pharmaceuticals v Celgene Corporation  Lexology Biocon inks patent litigation settlement pact with Celgene over bone marrow cancer medicine  The New Indian Express Sun Pharma settles patent dispute with US-based Celgene Corporation  Business Standard Hold onto your hats! - Expedited patent litigation in Australia  Lexology It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct'  FiercePharma Bristol Myers will likely settle the $6.4B Celgene CVR lawsuit at a discount, analyst says. Here's why  FiercePharma Celgene Announces Plans to Transfer Listing of Celgene's Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb  Business Wire Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company  Business Wire Biotech Says Celgene-BMS Deal Threatens Drug Development  Law360 Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company  Business Wire BMS/Celgene merger payout evaporates as CVR deadline passes -  pharmaphorum Case summary on the recent Australian pharmaceutical patent litigation - Juno Pharmaceuticals Pty Ltd v Celgene Corporation [2021] FCA 236  Lexology Bristol Myers Is Taking Full Advantage of its Celgene Acquisition  Motley Fool At CAGR 19.7%, CAR-T Cell Therapy Market Size to hit USD 19126.1 Mn by 2027 Says Brandessence Market Research  EIN News Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself  Law360 Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company  Business Wire Wellington Management Does Not Support Bristol-Myers Squibb's Acquisition of Celgene Corporation  Business Wire Celgene Can't 'Guess' How Rival Mylan Operates, Judge Says  Law360 Biocon Limited enters into a settlement agreement with Celgene Corp  Equity Bulls Celgene Sues Hikma To Block Revlimid Generic  Law360 Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLAŽ for $13.4 Billion  Business Wire Why Celgene's Beaten Down Stock Can Rise 28%  Investopedia Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal  Reuters Bristol-Myers to buy Celgene in a $74 billion deal; Celgene shares surge  CNBC Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline  Endpoints News Here's What Celgene Shareholders Are Getting From Bristol-Myers Squibb  Motley Fool Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal  Reuters Cancer Therapeutics Market Size to Gain Traction of $180.19 Billion, Growth Opportunities by 2026  EIN News Cadila Health settles patents case with US firm over anti-cancer drug Revlimid  Livemint BMS CEO Earned $20 Million in 2020, a 7% Increase Amidst a Global Pandemic  BioSpace Celgene Reports Third Quarter 2019 Operating and Financial Results  Business Wire Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain  TheStreet.com With Bristol-Myers CVR, Investors Can Bet on 3 Drugs in Celgene?s Pipeline  Barron's Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug  Reuters Celgene (CELG) Updates on R&D Deep Dive (Multiple Myeloma) - Slideshow  Seeking Alpha Ulcerative Colitis Market Expected to Shows Impressive Hike in Growth Rate by 2023  EIN News Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy  Business Wire Celgene Strikes Strategic Partnership With Evotec  Investopedia Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion  Business Wire Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition  Business Wire Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia  Business Wire Celgene repeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe finds  FiercePharma Cipla Gains Nearly 5% On Settlement of US Patent Litigation  NDTV Profit Should Celgene Investors Take Bristol's Money and Run?  Motley Fool Bristol-Myers to acquire Celgene in cash-and-stock deal with equity value of about $74 billion  MarketWatch Here's Where Things Went Wrong for Celgene Corporation in 2017  Motley Fool Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity  Scrip Celgene's Stock May See More Big Gains Ahead  Investopedia Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies  Business Wire Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings  Business Wire Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes  Business Wire Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results  Business Wire Celgene Offers High Growth At An Inexpensive Price  Seeking Alpha Editas Medicine and Celgene Corporation Amend Existing  GlobeNewswire Fast-Track Loss In EU For Celgene's CAR-T Cell Therapy  Pink Sheet Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020  Business Wire Is It Too Late to Buy Celgene Stock?  Motley Fool BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs  Pink Sheet Bristol-Myers Squibb Contingent Value Rights: Thinking Through The Options Around Litigation Financing  Seeking Alpha Turning Point Therapeutics Names Former Celgene Chairman  GlobeNewswire Bristol-Myers/Celgene: Win-Win Merger  Seeking Alpha Celgene Shares Slide as Key Bristol-Myers Investor Queries $74 Billion Takeover  TheStreet.com Celgene to buy Impact Biomedicines for up to $7 billion  Reuters Week Ahead in Mergers and Acquisitions: Sept. 13, 2021  Reuters Is Celgene a Buy?  Motley Fool Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy  Business Wire Celgene to Acquire Delinia, Inc.  Business Wire Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development  Business Wire Celgene Slumps Yet Again, This Time on Biomedicines Deal  Barron's The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski  Xconomy Celgene (CELG) Stock Will Eventually Break Out of Sideways Trend  TheStreet.com Bristol-Myers Squibb completes $74 billion acquisition of Celgene  MarketWatch Father and son advised on opposite sides of Bristol-Celgene deal  Reuters Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies  Business Wire Chimeric Therapeutics appoints Celgene veteran Dr George Matcham to the board  Proactive Investors Australia Former Celgene, Portola Lawyers Land New Big Pharma Roles  Bloomberg Law Celgene In 2018: A Look At The Long Thesis  Seeking Alpha Activist investor Starboard Value says it will oppose Bristol-Myers' $74 billion deal for Celgene  CNBC Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019  Business Wire FDA Delay for BMS' Liso-cel Likely Kills $9 Celgene CVR Hopes for Investors  BioSpace Deep Diving Celgene - Early Stages Of A Transition  Seeking Alpha Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?  Motley Fool Is Celgene A Growth Or A Value Stock?  Seeking Alpha Celgene to pay $280 million to settle off-label marketing case  Reuters Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program  FierceBiotech Bristol-Myers Squibb completes acquisition of Celgene  European Pharmaceutical Review
For more news about Celgene Corporati click here:
Celgene Corporati News
Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2021 - TR4DER.com, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources